Abbott launches Freenome’s colorectal cancer screening test

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 30 Sept, 14:58 UTC

Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.

businessscience

Sources

• T2Abbott launches Freenome’s colorectal cancer screening testBioPharma Dive / Healthcare Dive / MedTech Dive30 Sept, 14:58